DR info

Clinical trials : 39 / Drugs : 42 - (DrugBank : 32) / Drug target genes : 47 - Drug target pathways : 67

Drugs and their primary sponsors and trial info

A042917017
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2019   Phase 2   EUCTR2018-001094-25-IT   Italy;
Alpha-tocotrienol quinone
   PTC THERAPEUTICS, INC.
      2021   Phase 2;Phase 3   EUCTR2020-002100-39-ES   France;Germany;Italy;Spain;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-002100-39-SE   Australia;Canada;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-002100-39-FR   France;Germany;Italy;Spain;United Kingdom;United States;
Bupropion
   Abliva AB
      2020   Phase 1   NCT04643249   United Kingdom;
Caffeine
   Abliva AB
      2020   Phase 1   NCT04643249   United Kingdom;
CoenzymeQ10
   University of Florida
      2007   Phase 3   NCT00432744   Canada;United States;
Creatine
   Children's Hospital of Philadelphia
      2021   -   NCT04734626   United States;
Cysteamine Bitartrate
   Horizon Pharma USA, Inc.
      2015   Phase 2   NCT02473445   United States;
      2014   Phase 2   NCT02023866   United States;
Dexmedetomidine
   The University of Texas Health Science Center, Houston
      2014   -   NCT02053766   United States;
Dextromethorphan
   Abliva AB
      2020   Phase 1   NCT04643249   United Kingdom;
EPI-743
   National Human Genome Research Institute (NHGRI)
      2012   Phase 1/Phase 2   NCT01642056   United States;
EPI743
   PTC THERAPEUTICS, INC.
      2021   Phase 2;Phase 3   EUCTR2020-002100-39-ES   France;Germany;Italy;Spain;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-002100-39-SE   Australia;Canada;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-002100-39-FR   France;Germany;Italy;Spain;United Kingdom;United States;
Elamipretide
   Stealth BioTherapeutics Inc.
      2022   Phase 3   NCT05162768   United States;
      2016   Phase 2   NCT02976038   United States;
      2016   Phase 2   NCT02805790   United States;
Elamipretide (high dose)
   Stealth BioTherapeutics Inc.
      2015   Phase 1/Phase 2   NCT02367014   United States;
Elamipretide (intermediate dose)
   Stealth BioTherapeutics Inc.
      2015   Phase 1/Phase 2   NCT02367014   United States;
Elamipretide (low dose)
   Stealth BioTherapeutics Inc.
      2015   Phase 1/Phase 2   NCT02367014   United States;
Feburane
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2019   Phase 2   EUCTR2018-001094-25-IT   Italy;
Flurbiprofen
   Abliva AB
      2020   Phase 1   NCT04643249   United Kingdom;
Fluzone®
   Stanford University
      2010   Phase 4   NCT01831934   United States;
KH176
   Khondrion B.V.
      2021   Phase 2   EUCTR2020-003124-16-NL   Netherlands;
   Khondrion BV
      2016   Phase 2   NCT02909400   Netherlands;
      2016   Phase 2   EUCTR2016-001696-79-NL   Netherlands;
      2015   Phase 1   NCT02544217   Belgium;
KL1333
   Abliva AB
      2020   Phase 1   NCT04643249   United Kingdom;
      2019   Phase 1   NCT03888716   United Kingdom;
Low Residue Diet Intervention
   Newcastle University
      2017   -   NCT03388528   United Kingdom;
MTP-131
   Stealth BioTherapeutics Inc.
      2022   Phase 3   EUCTR2021-003907-16-HU   Australia;Denmark;Finland;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;United States;
Midazolam injection
   Abliva AB
      2020   Phase 1   NCT04643249   United Kingdom;
Omeprazole
   Abliva AB
      2020   Phase 1   NCT04643249   United Kingdom;
PTC743
   PTC THERAPEUTICS INC.
      2021   Phase 2;Phase 3   EUCTR2020-002100-39-IT   France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
   PTC THERAPEUTICS, INC.
      2021   Phase 2;Phase 3   EUCTR2020-002100-39-ES   France;Germany;Italy;Spain;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-002100-39-SE   Australia;Canada;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-002100-39-FR   France;Germany;Italy;Spain;United Kingdom;United States;
Pheburane
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2019   Phase 2   EUCTR2018-001094-25-IT   Italy;
Propofol
   The University of Texas Health Science Center, Houston
      2014   -   NCT02053766   United States;
RG2133 (2',3',5'-tri-O-acetyluridine)
   Repligen Corporation
      2003   Phase 1   NCT00060515   United States;
Reagila
   Semmelweis University, STIA-POC-2020
      2021   Phase 4   EUCTR2021-001268-58-HU   Hungary;
Repaglinide
   Abliva AB
      2020   Phase 1   NCT04643249   United Kingdom;
SPP-004
   Saitama Medical University Hospital
      2019   Phase 3   JPRN-JMA-IIA00406   Japan;
      2018   Phase 3   JPRN-JMA-IIA00358   Japan;
      2015   Phase 2   JPRN-JMA-IIA00214   Japan;
      2014   Phase 2   JPRN-JMA-IIA00200   Japan;
Sevoflurane
   The University of Texas Health Science Center, Houston
      2014   -   NCT02053766   United States;
   d sessler
      2006   -   NCT01001585   United States;
Sonlicromanol
   Khondrion B.V.
      2021   Phase 2   EUCTR2020-003124-16-NL   Netherlands;
   Khondrion BV
      2021   Phase 2   NCT04846036   Netherlands;
Vatiquinone
   PTC Therapeutics
      2020   Phase 2/Phase 3   NCT04378075   Italy;Spain;United Kingdom;United States;